<p>SummerHaven Investment Management LLC 在第三季度购买了 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免费报告）的新股份，根据该公司在最近向证券交易委员会（SEC）披露的信息。该基金购买了 38,200 股公司股票，价值约为 1,018,000 美元。根据其最近向证券交易委员会（SEC）提交的文件，SummerHaven Investment Management LLC 拥有约 0.08% 的 Amphastar Pharmaceuticals。</p>
<ul>
<li>在降息前值得购买的前两只小型医疗股</li>
</ul>
<p>其他大型投资者最近也买卖了该公司的股票。宾夕法尼亚州公共学校雇员退休系统在第二季度将其在 Amphastar Pharmaceuticals 的股份增加了 5.2%。宾夕法尼亚州公共学校雇员退休系统现在拥有 9,440 股公司股票，价值 217,000 美元，此前在上个季度购买了 465 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Amphastar Pharmaceuticals 的股份增加了 2.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 现在拥有 22,489 股公司股票，价值 652,000 美元，此前在上个季度购买了 613 股。Global Retirement Partners LLC 在第三季度将其在 Amphastar Pharmaceuticals 的持股增加了 219.0%。Global Retirement Partners LLC 现在拥有 1,024 股公司股票，价值 27,000 美元，此前在上个季度购买了 703 股。Farther Finance Advisors LLC 在第三季度将其在 Amphastar Pharmaceuticals 的持股增加了 356.0%。Farther Finance Advisors LLC 现在拥有 944 股公司股票，价值 25,000 美元，此前在上个季度购买了 737 股。最后，GAMMA Investing LLC 在第二季度将其在 Amphastar Pharmaceuticals 的持股增加了 62.2%。GAMMA Investing LLC 现在拥有 2,162 股公司股票，价值 50,000 美元，此前在上个季度购买了 829 股。65.09% 的股票由机构投资者和对冲基金持有。</p>
<h2>Amphastar Pharmaceuticals 股票下跌 1.3%</h2>
<p>Amphastar Pharmaceuticals 股票在周三开盘价为 26.25 美元。Amphastar Pharmaceuticals, Inc. 的 12 个月低点为 20.39 美元，12 个月高点为 37.38 美元。该公司的市值为 12.1 亿美元，市盈率为 11.62，市盈增长比率为 4.71，贝塔值为 0.89。公司的 50 日移动平均价格为 26.69 美元，200 日移动平均价格为 26.16 美元。公司的速动比率为 2.21，流动比率为 3.12，债务与股本比率为 0.78。</p>
<ul>
<li>前景看好的小型生物科技公司 Amphastar 迎来可操作的回调</li>
</ul>
<p>Amphastar Pharmaceuticals（NASDAQ:AMPH - 获取免费报告）最后一次公布财报是在 11 月 6 日，星期四。该公司报告每股收益为 0.93 美元，超出分析师一致预期的 0.83 美元，超出幅度为 0.10 美元。该公司在本季度的收入为 1.9184 亿美元，而分析师预期为 1.8690 亿美元。Amphastar Pharmaceuticals 的股本回报率为 19.70%，净利润率为 15.43%。作为一个整体，分析师预计 Amphastar Pharmaceuticals, Inc. 本年度将发布 3.49 的每股收益。</p>
<h2>内部人士买卖</h2>
<p>在其他 Amphastar Pharmaceuticals 的新闻中，董事 Floyd F. Petersen 在 11 月 13 日星期四出售了 16,679 股该股票。股份以平均价格 26.49 美元出售，总交易额为 441,826.71 美元。交易后，该董事在公司中持有 75,531 股，价值 2,000,816.19 美元。这代表其持股减少了 18.09%。该出售在向 SEC 提交的文件中披露，文件可在此链接查看。此外，董事 Richard K. Prins 在 11 月 25 日星期二出售了 4,179 股 Amphastar Pharmaceuticals 股票。股份以平均价格 27.10 美元出售，总交易额为 113,250.90 美元。交易完成后，该董事持有 35,183 股公司股票，价值约为 953,459.30 美元。该交易使其持股减少了 10.62%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士已出售 35,308 股公司股票，价值 931,637 美元。27.10% 的股票由公司内部人士持有。</p>
<h2>华尔街分析师观点</h2>
<p>一些研究分析师最近对 AMPH 股票发表了评论。巴克莱在 12 月 9 日星期二的研究报告中开始覆盖 Amphastar Pharmaceuticals 的股票。他们给予该公司 “持平” 的评级，目标价格为 30.00 美元。Zacks Research 在 11 月 14 日星期五的报告中将 Amphastar Pharmaceuticals 的评级从 “强力买入” 下调至 “持有”。Needham &amp; Company LLC 在 11 月 7 日星期五的研究报告中将 Amphastar Pharmaceuticals 的目标价格从 36.00 美元下调至 34.00 美元，并对该股票给予 “买入” 评级。最后，Weiss Ratings 在 12 月 29 日星期一的研究报告中重申了对 Amphastar Pharmaceuticals 股票的 “持有（c-）” 评级。两位股票研究分析师对该股票给予了买入评级，六位分析师对该公司给予了持有评级。根据 MarketBeat.com 的数据，Amphastar Pharmaceuticals 的共识评级为 “持有”，平均目标价格为 31.00 美元。</p>
<p><strong>获取我们对 Amphastar Pharmaceuticals 的最新分析</strong></p>
<h2>Amphastar Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Amphastar Pharmaceuticals, Inc. 是一家总部位于加利福尼亚州兰乔库卡蒙加的专业制药公司。成立于 2004 年，Amphastar 专注于可注射和吸入产品的开发、生产和商业化。该公司在加利福尼亚的生产设施生产针对紧急和慢性医疗条件的仿制药和专利配方。</p>
<p>Amphastar 的产品组合包括一系列可注射的仿制药，如肾上腺素、纳洛酮和利多卡因，服务于医院、急救医疗和零售药房渠道。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票超过 Amphastar Pharmaceuticals</li>
<li>美国的下一个权力举动从地下开始</li>
<li>你的签名缺失——在为时已晚之前采取行动</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
<li>Nvidia 的三个秘密合作伙伴</li>
</ul>
<p><strong>想看看其他对 AMPH 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Amphastar Pharmaceuticals 吗？</h2>
<p>在考虑 Amphastar Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Amphastar Pharmaceuticals 并不在名单上。</p>
<p>虽然 Amphastar Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

美国制药 ETF - iShares

Amphastar制药

<p>SummerHaven Investment Management LLC 在第三季度收购了价值 102 万美元的 Amphastar Pharmaceuticals 股份，购买了 38,200 股。其他机构投资者也增加了他们的持股。Amphastar 的股票目前下跌 1.3%，交易价格为 26.25 美元，市值为 12.1 亿美元。该公司报告每股收益为 0.93 美元，超出预期。近期发生了内部人士的股票出售，董事们减少了他们的持股。分析师对该股票的评级不一，巴克莱给予其 “持平” 评级，并设定 30 美元的目标价</p>

<p>SummerHaven Investment Management LLC bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 38,200 shares of the company's stock, valued at approximately $1,018,000. SummerHaven Investment Management LLC owned about 0.08% of Amphastar Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>SummerHaven Investment Management LLC 在第三季度购买了 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免费报告）的新股份，根据该公司在最近向证券交易委员会（SEC）披露的信息。该基金购买了 38,200 股公司股票，价值约为 1,018,000 美元。根据其最近向证券交易委员会（SEC）提交的文件，SummerHaven Investment Management LLC 拥有约 0.08% 的 Amphastar Pharmaceuticals。</p>
</div><ul>
<li>Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>在降息前值得购买的前两只小型医疗股</li>
</ul>
</div><p>Other large investors have also recently bought and sold shares of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Amphastar Pharmaceuticals by 5.2% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,440 shares of the company's stock worth $217,000 after purchasing an additional 465 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Amphastar Pharmaceuticals by 2.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company's stock valued at $652,000 after buying an additional 613 shares in the last quarter. Global Retirement Partners LLC increased its holdings in Amphastar Pharmaceuticals by 219.0% during the third quarter. Global Retirement Partners LLC now owns 1,024 shares of the company's stock worth $27,000 after buying an additional 703 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in Amphastar Pharmaceuticals by 356.0% during the third quarter. Farther Finance Advisors LLC now owns 944 shares of the company's stock worth $25,000 after buying an additional 737 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Amphastar Pharmaceuticals by 62.2% during the second quarter. GAMMA Investing LLC now owns 2,162 shares of the company's stock worth $50,000 after acquiring an additional 829 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他大型投资者最近也买卖了该公司的股票。宾夕法尼亚州公共学校雇员退休系统在第二季度将其在 Amphastar Pharmaceuticals 的股份增加了 5.2%。宾夕法尼亚州公共学校雇员退休系统现在拥有 9,440 股公司股票，价值 217,000 美元，此前在上个季度购买了 465 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Amphastar Pharmaceuticals 的股份增加了 2.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 现在拥有 22,489 股公司股票，价值 652,000 美元，此前在上个季度购买了 613 股。Global Retirement Partners LLC 在第三季度将其在 Amphastar Pharmaceuticals 的持股增加了 219.0%。Global Retirement Partners LLC 现在拥有 1,024 股公司股票，价值 27,000 美元，此前在上个季度购买了 703 股。Farther Finance Advisors LLC 在第三季度将其在 Amphastar Pharmaceuticals 的持股增加了 356.0%。Farther Finance Advisors LLC 现在拥有 944 股公司股票，价值 25,000 美元，此前在上个季度购买了 737 股。最后，GAMMA Investing LLC 在第二季度将其在 Amphastar Pharmaceuticals 的持股增加了 62.2%。GAMMA Investing LLC 现在拥有 2,162 股公司股票，价值 50,000 美元，此前在上个季度购买了 829 股。65.09% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Amphastar Pharmaceuticals Stock Down 1.3%</h2>
<div class="lb-trans"><h2>Amphastar Pharmaceuticals 股票下跌 1.3%</h2>
</div><p>Amphastar Pharmaceuticals stock opened at $26.25 on Wednesday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.39 and a twelve month high of $37.38. The stock has a market cap of $1.21 billion, a P/E ratio of 11.62, a P/E/G ratio of 4.71 and a beta of 0.89. The company's 50-day moving average price is $26.69 and its two-hundred day moving average price is $26.16. The company has a quick ratio of 2.21, a current ratio of 3.12 and a debt-to-equity ratio of 0.78.</p>
<div class="lb-trans"><p>Amphastar Pharmaceuticals 股票在周三开盘价为 26.25 美元。Amphastar Pharmaceuticals, Inc. 的 12 个月低点为 20.39 美元，12 个月高点为 37.38 美元。该公司的市值为 12.1 亿美元，市盈率为 11.62，市盈增长比率为 4.71，贝塔值为 0.89。公司的 50 日移动平均价格为 26.69 美元，200 日移动平均价格为 26.16 美元。公司的速动比率为 2.21，流动比率为 3.12，债务与股本比率为 0.78。</p>
</div><ul>
<li>Promising Small Biotech Amphastar Sees Actionable Pullback</li>
</ul>
<div class="lb-trans"><ul>
<li>前景看好的小型生物科技公司 Amphastar 迎来可操作的回调</li>
</ul>
</div><p>Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, topping analysts' consensus estimates of $0.83 by $0.10. The company had revenue of $191.84 million for the quarter, compared to analyst estimates of $186.90 million. Amphastar Pharmaceuticals had a return on equity of 19.70% and a net margin of 15.43%. As a group, analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current year.</p>
<div class="lb-trans"><p>Amphastar Pharmaceuticals（NASDAQ:AMPH - 获取免费报告）最后一次公布财报是在 11 月 6 日，星期四。该公司报告每股收益为 0.93 美元，超出分析师一致预期的 0.83 美元，超出幅度为 0.10 美元。该公司在本季度的收入为 1.9184 亿美元，而分析师预期为 1.8690 亿美元。Amphastar Pharmaceuticals 的股本回报率为 19.70%，净利润率为 15.43%。作为一个整体，分析师预计 Amphastar Pharmaceuticals, Inc. 本年度将发布 3.49 的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 16,679 shares of the stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $26.49, for a total transaction of $441,826.71. Following the transaction, the director owned 75,531 shares in the company, valued at $2,000,816.19. This represents a 18.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Richard K. Prins sold 4,179 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $27.10, for a total transaction of $113,250.90. Following the completion of the sale, the director owned 35,183 shares of the company's stock, valued at approximately $953,459.30. The trade was a 10.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 35,308 shares of company stock valued at $931,637. 27.10% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Amphastar Pharmaceuticals 的新闻中，董事 Floyd F. Petersen 在 11 月 13 日星期四出售了 16,679 股该股票。股份以平均价格 26.49 美元出售，总交易额为 441,826.71 美元。交易后，该董事在公司中持有 75,531 股，价值 2,000,816.19 美元。这代表其持股减少了 18.09%。该出售在向 SEC 提交的文件中披露，文件可在此链接查看。此外，董事 Richard K. Prins 在 11 月 25 日星期二出售了 4,179 股 Amphastar Pharmaceuticals 股票。股份以平均价格 27.10 美元出售，总交易额为 113,250.90 美元。交易完成后，该董事持有 35,183 股公司股票，价值约为 953,459.30 美元。该交易使其持股减少了 10.62%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士已出售 35,308 股公司股票，价值 931,637 美元。27.10% 的股票由公司内部人士持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of research analysts have recently commented on AMPH shares. Barclays assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, December 9th. They issued an &#34;equal weight&#34; rating and a $30.00 price objective for the company. Zacks Research cut Amphastar Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, November 14th. Needham &amp; Company LLC dropped their price objective on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, November 7th. Finally, Weiss Ratings reaffirmed a &#34;hold (c-)&#34; rating on shares of Amphastar Pharmaceuticals in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Amphastar Pharmaceuticals has a consensus rating of &#34;Hold&#34; and an average price target of $31.00.</p>
<div class="lb-trans"><p>一些研究分析师最近对 AMPH 股票发表了评论。巴克莱在 12 月 9 日星期二的研究报告中开始覆盖 Amphastar Pharmaceuticals 的股票。他们给予该公司 “持平” 的评级，目标价格为 30.00 美元。Zacks Research 在 11 月 14 日星期五的报告中将 Amphastar Pharmaceuticals 的评级从 “强力买入” 下调至 “持有”。Needham &amp; Company LLC 在 11 月 7 日星期五的研究报告中将 Amphastar Pharmaceuticals 的目标价格从 36.00 美元下调至 34.00 美元，并对该股票给予 “买入” 评级。最后，Weiss Ratings 在 12 月 29 日星期一的研究报告中重申了对 Amphastar Pharmaceuticals 股票的 “持有（c-）” 评级。两位股票研究分析师对该股票给予了买入评级，六位分析师对该公司给予了持有评级。根据 MarketBeat.com 的数据，Amphastar Pharmaceuticals 的共识评级为 “持有”，平均目标价格为 31.00 美元。</p>
</div><p><strong>Get Our Latest Analysis on Amphastar Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Amphastar Pharmaceuticals 的最新分析</strong></p>
</div><h2>Amphastar Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Amphastar Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company's manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.</p>
<div class="lb-trans"><p>Amphastar Pharmaceuticals, Inc. 是一家总部位于加利福尼亚州兰乔库卡蒙加的专业制药公司。成立于 2004 年，Amphastar 专注于可注射和吸入产品的开发、生产和商业化。该公司在加利福尼亚的生产设施生产针对紧急和慢性医疗条件的仿制药和专利配方。</p>
</div><p>Amphastar's portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.</p>
<div class="lb-trans"><p>Amphastar 的产品组合包括一系列可注射的仿制药，如肾上腺素、纳洛酮和利多卡因，服务于医院、急救医疗和零售药房渠道。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Amphastar Pharmaceuticals</li>
<li>America's Next Power Move Starts Underground</li>
<li>Your Signature Is Missing – Act Before It’s Too Late</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li>
<li>Nvidia’s 3 Secret Partners</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Amphastar Pharmaceuticals</li>
<li>美国的下一个权力举动从地下开始</li>
<li>你的签名缺失——在为时已晚之前采取行动</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
<li>Nvidia 的三个秘密合作伙伴</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AMPH?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 AMPH 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMPH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amphastar Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Amphastar Pharmaceuticals 吗？</h2>
</div><p>Before you consider Amphastar Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Amphastar Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Amphastar Pharmaceuticals 并不在名单上。</p>
</div><p>While Amphastar Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Amphastar Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

SummerHaven Investment Management LLC 在 Amphastar 制药公司持有价值 102 万美元的头寸